StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 10 Jul 2026 16:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 4 AGIOS PHARMACEUTICALS, For: Jul 08 Filed by: Backstrom Jay T. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+08++Filed+by%3A+Backstrom+Jay+T./26757538.html si-local-file:///var/storage/secattach/20260710/26757538.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+08++Filed+by%3A+Backstrom+Jay+T./26757538.html Fri, 10 Jul 2026 16:18:00 -0400 AGIO O.07489851 Form 4 AGIOS PHARMACEUTICALS, For: Jul 08 Filed by: Backstrom Jay T. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+08++Filed+by%3A+Backstrom+Jay+T./26757538.html si-local-file:///var/storage/secattach/20260710/26757538.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+08++Filed+by%3A+Backstrom+Jay+T./26757538.html Fri, 10 Jul 2026 16:18:00 -0400 AGIO O.07489851 Agios Pharma (AGIO) PT Raised to $32 at RBC Capital http://www.streetinsider.com/Analyst+PT+Change/Agios+Pharma+%28AGIO%29+PT+Raised+to+%2432+at+RBC+Capital/26738633.html RBC Capital analyst Luca Issi raised the price target on Agios Pharma (NASDAQ: AGIO) to $32.00 (from $28.00) while maintaining a Sector Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Agios+Pharma+%28AGIO%29+PT+Raised+to+%2432+at+RBC+Capital/26738633.html Tue, 07 Jul 2026 07:55:47 -0400 AGIO Agios Pharma (AGIO) PT Raised to $41 at Truist Securities http://www.streetinsider.com/Analyst+PT+Change/Agios+Pharma+%28AGIO%29+PT+Raised+to+%2441+at+Truist+Securities/26738269.html Truist Securities analyst Greg Renza raised the price target on Agios Pharma (NASDAQ: AGIO) to $41.00 (from $36.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Agios+Pharma+%28AGIO%29+PT+Raised+to+%2441+at+Truist+Securities/26738269.html Tue, 07 Jul 2026 07:08:40 -0400 AGIO FDA grants priority review to Agios' mitapivat for sickle cell disease http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html <p>Agios Pharmaceuticals (Nasdaq: AGIO) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, granting it Priority Review. The FDA's PDUFA goal date is November 1, 2026.</p> <p>The sNDA was submitted under the FDA's accelerated approval pathway. Priority Review designation shortens the standard review timeline from 10 months to six months and is granted to applications for medicines that may offer significant improvements in safety or efficacy for serious conditions.</p> <p>The application is based on data from the RISE UP Phase 2 and Phase 3 trials, which were global, randomized, http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html Tue, 07 Jul 2026 07:00:54 -0400 A.06822034 AGIO O.07489851 O.20026344 FDA grants priority review to Agios' mitapivat for sickle cell disease http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html <p>Agios Pharmaceuticals (Nasdaq: AGIO) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, granting it Priority Review. The FDA's PDUFA goal date is November 1, 2026.</p> <p>The sNDA was submitted under the FDA's accelerated approval pathway. Priority Review designation shortens the standard review timeline from 10 months to six months and is granted to applications for medicines that may offer significant improvements in safety or efficacy for serious conditions.</p> <p>The application is based on data from the RISE UP Phase 2 and Phase 3 trials, which were global, randomized, http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html Tue, 07 Jul 2026 07:00:54 -0400 A.06822034 AGIO O.07489851 O.20026344 FDA grants priority review to Agios' mitapivat for sickle cell disease http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html <p>Agios Pharmaceuticals (Nasdaq: AGIO) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, granting it Priority Review. The FDA's PDUFA goal date is November 1, 2026.</p> <p>The sNDA was submitted under the FDA's accelerated approval pathway. Priority Review designation shortens the standard review timeline from 10 months to six months and is granted to applications for medicines that may offer significant improvements in safety or efficacy for serious conditions.</p> <p>The application is based on data from the RISE UP Phase 2 and Phase 3 trials, which were global, randomized, http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html Tue, 07 Jul 2026 07:00:54 -0400 A.06822034 AGIO O.07489851 O.20026344 FDA grants priority review to Agios' mitapivat for sickle cell disease http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html <p>Agios Pharmaceuticals (Nasdaq: AGIO) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, granting it Priority Review. The FDA's PDUFA goal date is November 1, 2026.</p> <p>The sNDA was submitted under the FDA's accelerated approval pathway. Priority Review designation shortens the standard review timeline from 10 months to six months and is granted to applications for medicines that may offer significant improvements in safety or efficacy for serious conditions.</p> <p>The application is based on data from the RISE UP Phase 2 and Phase 3 trials, which were global, randomized, http://www.streetinsider.com/FDA/FDA+grants+priority+review+to+Agios%27+mitapivat+for+sickle+cell+disease/26738203.html Tue, 07 Jul 2026 07:00:54 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Press+Releases/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html <ul type="disc"><li>FDA’s PDUFA goal date is November 1, 2026<br/><br/></li><li>If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease<br/><br/></li></ul> <p>CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for http://www.streetinsider.com/Globe+Newswire/U.S.+FDA+Grants+Priority+Review+to+Agios%E2%80%99+sNDA+for+Mitapivat+in+Sickle+Cell+Disease/26738195.html Tue, 07 Jul 2026 07:00:00 -0400 A.06822034 AGIO O.07489851 O.20026344 Agios Pharma (AGIO) PT Raised to $46 at BofA Securities http://www.streetinsider.com/Analyst+PT+Change/Agios+Pharma+%28AGIO%29+PT+Raised+to+%2446+at+BofA+Securities/26737593.html BofA Securities analyst Alec W. Stranahan raised the price target on Agios Pharma (NASDAQ: AGIO) to $46.00 (from $40.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Agios+Pharma+%28AGIO%29+PT+Raised+to+%2446+at+BofA+Securities/26737593.html Tue, 07 Jul 2026 05:16:26 -0400 AGIO Form SCHEDULE 13G AGIOS PHARMACEUTICALS, Filed by: D. E. SHAW &amp; CO, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26727508.html si-local-file:///var/storage/secattach/20260702/26727508.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26727508.html Thu, 02 Jul 2026 16:05:00 -0400 AGIO O.07489851 Form SCHEDULE 13G AGIOS PHARMACEUTICALS, Filed by: D. E. SHAW &amp; CO, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26727508.html si-local-file:///var/storage/secattach/20260702/26727508.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26727508.html Thu, 02 Jul 2026 16:05:00 -0400 AGIO O.07489851 Form 4 AGIOS PHARMACEUTICALS, For: Jul 01 Filed by: Gheuens Sarah http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727455.html si-local-file:///var/storage/secattach/20260702/26727455.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727455.html Thu, 02 Jul 2026 16:03:00 -0400 AGIO O.07489851 Form 4 AGIOS PHARMACEUTICALS, For: Jul 01 Filed by: Gheuens Sarah http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727455.html si-local-file:///var/storage/secattach/20260702/26727455.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AGIOS+PHARMACEUTICALS%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727455.html Thu, 02 Jul 2026 16:03:00 -0400 AGIO O.07489851 Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah http://www.streetinsider.com/SEC+Filings/Form++144++++++++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+Gheuens+Sarah/26720673.html si-local-file:///var/storage/secattach/20260701/26720673.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+Gheuens+Sarah/26720673.html Wed, 01 Jul 2026 16:08:00 -0400 AGIO O.07489851 Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah http://www.streetinsider.com/SEC+Filings/Form++144++++++++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+Gheuens+Sarah/26720673.html si-local-file:///var/storage/secattach/20260701/26720673.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AGIOS+PHARMACEUTICALS%2C+++++++++++++++++Filed+by%3A+Gheuens+Sarah/26720673.html Wed, 01 Jul 2026 16:08:00 -0400 AGIO O.07489851 Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET http://www.streetinsider.com/Press+Releases/Agios+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+July+30+at+8%3A00+a.m.+ET/26701853.html <p>CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights.</p> <p>The live webcast will be accessible on the Investors section of the company’s website (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=iCmeZkB4CgCj9PhdRDBfePGSVOX6QVTdySeKBM--ebjy49GrrIkAGN3fap2yaupYWPoDsWOi21CIZUlUbjbNyw==" rel="nofollow" target="_blank">www.agios.com</a>) under the “Events &amp; Presentations” tab. A replay of the webcast will be available on the company’s website approximately http://www.streetinsider.com/Press+Releases/Agios+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+July+30+at+8%3A00+a.m.+ET/26701853.html Mon, 29 Jun 2026 07:00:00 -0400 AGIO O.07489851 Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET http://www.streetinsider.com/Press+Releases/Agios+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+July+30+at+8%3A00+a.m.+ET/26701853.html <p>CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights.</p> <p>The live webcast will be accessible on the Investors section of the company’s website (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=iCmeZkB4CgCj9PhdRDBfePGSVOX6QVTdySeKBM--ebjy49GrrIkAGN3fap2yaupYWPoDsWOi21CIZUlUbjbNyw==" rel="nofollow" target="_blank">www.agios.com</a>) under the “Events &amp; Presentations” tab. A replay of the webcast will be available on the company’s website approximately http://www.streetinsider.com/Press+Releases/Agios+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+July+30+at+8%3A00+a.m.+ET/26701853.html Mon, 29 Jun 2026 07:00:00 -0400 AGIO O.07489851